You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,383,610


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,383,610
Title:Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Abstract: Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.
Inventor(s): Cvetovich; Raymond (Jersey City, NJ), Warchol; Tadeusz (Northborough, MA)
Assignee: Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:12/471,758
Patent Claims: 1. A polymorph of a tosylate salt of Compound 1: ##STR00006## selected from the group consising of: a polymorph characterized by an X-ray powder diffraction pattern including peaks at approximately 8.06, 13.02, and 18.83 .degree.2.theta. using Cu K.alpha. radiation, a polymorph characterized by an X-ray powder diffraction pattern including peaks at approximately 5.11 and 15.60 .degree.2.theta. using Cu K.alpha. radiation, and a polymorph characterized by an X-ray powder diffraction pattern including peaks at approximately 11.88 and 16.12 .degree.2.theta. using Cu K.alpha. radiation.

2. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern including peaks at approximately 8.06, 11.41, 13.02, 18.83, 20.54, and 24.53 .degree.2.theta. using Cu K.alpha. radiation.

3. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern including peaks at approximately 5.60, 8.06, 8.57, 11.41, 13.02, 15.58, 18.83, 20.54, and 24.53 .degree.2.theta. using Cu K.alpha. radiation.

4. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 8.

5. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern including peaks at approximately 5.11, 8.89, 10.34, 11.76, and 15.60 .degree.2.theta. using Cu K.alpha. radiation.

6. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern including peaks at approximately 5.11, 8.89, 10.34, 11.76, 13.70, 14.81, and 15.60 .degree.2.theta. using Cu K.alpha. radiation.

7. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 10.

8. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern including peaks at approximately 7.82, 11.88, 16.12, and 21.46 .degree.2.theta. using Cu K.alpha. radiation.

9. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern including peaks at approximately 7.82, 11.88, 12.68, 16.12, 18.63, 21.46, and 23.74 .degree.2.theta. using Cu K.alpha. radiation.

10. The polymorph of claim 1, characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 9.

11. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1: ##STR00007## from isopropanol.

12. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1: ##STR00008## from a ketone.

13. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1: ##STR00009## from acetone, methyl ethyl ketone or methyl pentanone.

14. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1: ##STR00010## from ethyl acetate.

15. The polymorph of claim 1 obtained by crystallizing a tosylate salt of Compound 1: ##STR00011## from dichloromethane.

16. A pharmaceutical composition comprising the polymorph of claim 1 and a pharmaceutically acceptable diluent, excipient or carrier.

17. The pharmaceutical composition of claim 16, wherein the polymorph is in a pure form.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.